Awakn Life Sciences Corp. reported earnings results for the third quarter and nine months ended October 31, 2022. For the third quarter, the company reported revenue was CAD 0.430504 million compared to CAD 0.031737 million a year ago. Net loss was CAD 1.47 million compared to CAD 2.95 million a year ago. Basic loss per share from continuing operations was CAD 0.05 compared to CAD 0.12 a year ago.
For the nine months, revenue was CAD 1.02 million compared to CAD 0.031737 million a year ago. Net loss was CAD 6.49 million compared to CAD 11.91 million a year ago. Basic loss per share from continuing operations was CAD 0.24 compared to CAD 0.57 a year ago.